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Identification and targeted management of a
neurodegenerative disorder caused by biallelic mutations in
SLC5A6
Alicia B. Byrne 1,2, Peer Arts 1, Steven W. Polyak2,3, Jinghua Feng2,4, Andreas W. Schreiber2,3,4, Karin S. Kassahn3,5,
Christopher N. Hahn 1,2,5,6, Dylan A. Mordaunt 7, Janice M. Fletcher5, Jillian Lipsett8, Drago Bratkovic6,7, Grant W. Booker3,
Nicholas J. Smith6,9,10* and Hamish S. Scott 1,2,4,5,6,10*
We describe a sibling pair displaying an early infantile-onset, progressive neurodegenerative phenotype, with symptoms of
developmental delay and epileptic encephalopathy developing from 12 to 14 months of age. Using whole exome sequencing,
compound heterozygous variants were identified in SLC5A6, which encodes the sodium-dependent multivitamin transporter
(SMVT) protein. SMVT is an important transporter of the B-group vitamins biotin, pantothenate, and lipoate. The protein is
ubiquitously expressed and has major roles in vitamin uptake in the digestive system, as well as transport of these vitamins across
the blood–brain barrier. Pathogenicity of the identified variants was demonstrated by impaired biotin uptake of mutant SMVT.
Identification of this vitamin transporter as the genetic basis of this disorder guided targeted therapeutic intervention, resulting
clinically in improvement of the patient’s neurocognitive and neuromotor function. This is the second report of biallelic mutations
in SLC5A6 leading to a neurodegenerative disorder due to impaired biotin, pantothenate and lipoate uptake. The genetic and
phenotypic overlap of these cases confirms mutations in SLC5A6 as the genetic cause of this disease phenotype. Recognition of the
genetic disorder caused by SLC5A6 mutations is essential for early diagnosis and to facilitate timely intervention by triple vitamin
(biotin, pantothenate, and lipoate) replacement therapy.
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INTRODUCTION
While individually rare, inborn errors of metabolism are over-
represented amongst the childhood neurodegenerative diseases,
with an increasing number of novel disorders identified.1 These
disorders are caused by perturbed transport or processing of
essential metabolites and have a profound impact on nervous
system development and function. In the majority of cases, this
effect is compounded by a lack of effective therapy. However,
contemporary elucidation of the molecular abnormalities under-
pinning these disorders is informing therapeutic development,
with early intervention translating to favourable clinical responses
in a growing number of cases.2
Highlighting the importance of recognising novel, ultra-rare
disorders with the potential for personalised therapeutic inter-
vention is the recently described disorder of sodium-dependent
multivitamin transport (SMVT).3,4 The SMVT protein (encoded by
SLC5A6) is ubiquitously expressed and plays a major role in the
uptake of biotin, pantothenate and lipoate in the digestive system,
as well as in transporting these B-group vitamins across the
blood–brain barrier. This report showed that pathogenic muta-
tions in SLC5A6 resulted in aberrant cellular uptake of these critical
organic cofactors, manifesting clinically in a single patient as a
multisystem disease with infantile neurocognitive regression.4
Here we describe a second, non-consanguineous sibling pair,
presenting in early infancy with a progressive neurodegenerative
phenotype. Whole exome sequencing (WES) revealed compound
heterozygous mutations in SLC5A6, with pathogenicity of the
identified variants demonstrated by impaired biotin uptake of
mutant SMVT. Targeted vitamin replacement therapy was initiated
resulting in sustained clinical improvement, providing further
evidentiary support for disease causality and expanding the
recognised spectrum of inborn diseases of biotin metabolism.4–8
RESULTS
Family presentation
Two siblings (II-1 and II-2) presenting with a profound neurode-
velopmental delay during infancy were born to unaffected,
unrelated parents (I-1 and I-2). Before a molecular diagnosis was
determined for II-1 and II-2, the parents chose an ovum donor (I-3)
to reduce the risk of recurrence in their third child (II-3) (Fig. 1a).
Detailed clinical descriptions of both affected siblings can be
found in the supplementary information and are summarised in
Table 1. In brief, both siblings were born at term without
complication following a benign antenatal period. Birth occipito-
frontal head circumference (OFC) was at the 50th centile with 34 cm
(II-1) and 34.5 cm (II-2), followed by postnatal reduction (2nd–10th
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centile) in both children. Early developmental progress was age
appropriate with a plateau in global development from 14 months
(II-1) and 12 months (II-2). II-1 walked independently (15 months),
however regressed to crawling (20 months) and non-ambulation
(24 months). Her vocabulary of 15–20 words (15 months) retracted
to 10 words (23 months), only using ‘mum’ and ‘dad’ by 30 months.
II-2 commenced few independent steps at 12 months and used a
walking assist device until 5 years and 6 months when he regressed
to crawling. His vocabulary of 10 single words by 15 months
regressed to non-verbal by 24 months.
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Neurological assessment demonstrated progressive truncal
ataxia with dyskinetic appendicular movements from 14 months
(II-1) and 12 months (II-2). II-2 developed mixed semiology
seizures including focal dyscognitive, absence, tonic spasms and
generalised convulsive seizures with electrographic features of
encephalopathy with generalised and independent multifocal
spike-wave discharges (Supplementary Fig. 1A). The seizures
proved well controlled on a regimen of levetiracetam, topiramate
and vigabatrin. Refractory cyclical vomiting (II-2) was present from
3 years, 5 months of age. As neurophysiological assessment,
neuroimaging, biochemical, single-gene testing and mitochon-
drial genome sequencing did not provide a diagnosis for this
family, WES was performed.
At 2 years 7 months, II-1 died secondary to acute gastro-
intestinal haemorrhage following perforation of a duodenal ulcer.
Post-mortem examination revealed a small cerebrum and
cerebellum for age (brain weight 977 g), with preservation of
overall neural architecture. Cardiomegaly, hepatic congestion and
aspiration pneumonia were also observed, likely secondary to pre-
mortem cardiopulmonary resuscitation. Histopathological analysis
demonstrated a global increase in glial density with reactive
gliotic change. Axonal spheroids, up to 100 μm in diameter, were
ubiquitously present (Supplementary Fig. 3A). Peripheral nerves
demonstrated variable axonal irregularity and patchy denervation
atrophy was evident within skeletal muscle.
Treatment outcomes
Upon identification of the pathogenic SLC5A6 mutations, II-2
commenced parenterally administered triple vitamin replacement
therapy at 7 years and 1 month of age, with doses of Biotin
(10 mg, intramuscular), Dexpanthenol (250 mg, intramuscular) and
α-lipoic acid (300 mg, intravenous) given weekly. To date,
treatment has improved the overall condition of II-2 (Table 1);
he restarted crawling and climbing to a standing position (+1
year, 8 months) and regained use of a walk-assist frame (+3 years,
4 months). He demonstrated improved attention and persistence
at tasks (+1 year, 11 months), and from +3 years is more
communicative, regaining a limited (4–6 words) vocabulary at +5
years, with improved consistency in following single-step direc-
tions. His seizure control remains effective and there has been
interval improvement towards normal in background electro-
graphic activity, albeit with persisting epileptiform discharges
(Supplementary Fig. 1B). His cyclical vomiting has attenuated in
frequency and duration. His nerve conduction studies confirm
near total and sustained resolution of peripheral neuropathy from
+3 years.
Identification of candidate variants
WES resulted in an average coverage of the exome of 72.21 (II-1)
and 88.19 (II-2), with 90.4% (II-1) and 91.8% (II-2) of the targets
being covered at least 10× (Supplementary Table 1). Filtering for
rare (<1% in population databases), non-synonymous variants
resulted in 487 variants for II-1 and 454 variants for II-2. Overlap
analysis between the two siblings did not identify variants in
OMIM-reported genes known to cause neurodegeneration. Two
variants were however identified in SLC5A6, V141Afs*34 (Chr2
(GRCh37):g.27,429,780GCA>G; c.422_423delTG), and R400T (Chr2
(GRCh37):g.27,426,109C>G; c.1199G>C).
Sanger sequencing of the unaffected parents showed each was
a heterozygous carrier of one variant, p.V141Afs*34 (maternal) and
p.R400T (paternal) (Fig. 1a), and confirmed the presence, in
compound heterozygosity, of both variants in the affected
individuals. The unaffected half-sibling was not tested for the
paternal allele.
Evaluation of SLC5A6 variants
Qualitative analysis of SLC5A6 wild-type and mutant allele
expression was performed by Sanger sequencing of patient cDNA.
Expression of the V141Afs*34 truncated allele was decreased
compared to wild-type. The R400T allele was stably expressed and
was the only allele present at that location in the compound
heterozygous, affected children (Fig. 1b).
Biotin uptake assays were initially performed on primary dermal
fibroblasts. After growing the cells for 24 h in media supplemen-
ted with tritium-labelled biotin, cell lysates were harvested and
the amount of radioactivity quantitated by scintillation counting.
Whilst decreased biotin uptake was observed in cells derived from
the compound heterozygous, affected children relative to their
heterozygous, unaffected parents, this difference was not
statistically significantly different compared to controls (Supple-
mentary Fig. 4A).
Biotin uptake was then assessed in cultured HeLa cells
transiently transfected with expression constructs for wild-type
and mutant SLC5A6. Cell lysates were again harvested and
quantitated after 24 h of growth in media containing radiolabelled
biotin. Expression of wild-type SMVT significantly increased biotin
uptake by 1.5-fold over the empty vector negative control (p=
0.008) (Fig. 1c). In contrast, the uptake of biotin by the R400T and
V141Afs*34 mutant SMVT proteins was not different from uptake
in the empty vector control (Fig. 1c). This result confirmed both
variants result in a severe loss of function.
DISCUSSION
Here we provide consolidative evidence implicating disordered
SMVT function in an infantile neurodegenerative phenotype.
SMVT is a sodium-dependent transporter of biotin, pantothenate
and lipoate; organic enzyme co-factors which are integral to fatty
acid metabolism and cellular energy production (Fig. 1d, e).9,10
It is notable that prior defined inborn errors of biotin
metabolism, holocarboxylase synthetase deficiency (HLCS;
MIM#253270) and biotinidase deficiency (BTD; MIM#253260) share
phenotypic similarities with the cases described herein. Untreated
patients demonstrate progressive cognitive and neuromotor
decline, often with prominent seizures, with variable response
to biotin replacement therapy.5–7,11 Further clinical overlap is
evident amongst inborn mutations affecting pantothenate
Fig. 1 Biotin, pantothenate and lipoate-dependent metabolic pathways and the effect of identified variants in SLC5A6. a Pedigree of the non-
consanguineous family. b Chromatograms from Sanger sequencing of patient DNA compared to cDNA show decreased expression of the
V141Afs*34 allele and stable expression of the R400T allele. c Uptake of radiolabelled biotin by HeLa cells transfected with empty vector, wild-
type or mutant SMVT expression constructs. Uptake by mutant constructs is decreased compared to wild-type (p= 0.008) and not significantly
different to empty vector (p > 0.05). Data show the mean and standard error of the mean (n= 4). d SCL5A6 function and e Enzymes for which
the vitamins Biotin (green), Pantothenate (blue) and Alpha-lipoic acid (red) play a role as important cofactors in: the degradation pathways of
the amino acids leucine, isoleucine, valine and glycine; glucose energy metabolism; the TCA cycle; and fatty acid oxidation metabolism. All
pathways apart from the glycine cleavage system play a fundamental role in cellular energy production. The pathways involved with fatty acid
metabolism and branch chain amino acid breakdown occur almost exclusively in the liver. BBB blood–brain barrier, BCKD Branch chain
ketoacid dehydrogenase, CNS central nervous system, KDHC ketoglutarate dehydrogenase complex, PC pyruvate carboxylase, PCC propionyl-
CoA carboxylase, PDHC pyruvate dehdrogenase complex, 3MCCC 3-methyl crotonyl-CoA carboxylase
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Table 1. Clinical features and outcome following treatment of the three patients with biallelic SLC5A6 mutations causing SMVT deficiency


















Microcephaly Yes, relativec Yes, relativec Yes








Spasticity No No Yes
Hyperreflexia Yes Yesd NR





Hyperacusis Yes Yes (resolved pre-treatment) NR





Neuroimaging (MRI)f No cerebral atrophy









(central segmental tract & peritrigonal regions)
Mega cisterna magna
1H-MRS (SVS) [31 and 144ms; basal ganglia/








Not done Background slowing (encephalopathy)










Skeletal muscle biopsy: denervation
atrophy











GI haemorrhage Yesk Yesl Yesm










ECG: non-specific ST & T-wave changeso
NR
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metabolism, which are implicated as causative of pantothenate
kinase-associated neurodegeneration (PKAN/NBIA1, PANK2;
MIM#234200) and COASY protein-associated neurodegeneration
(CoPAN/NBIA6, COASY; MIM#615643). In addition, neuroaxonal
spheroids which were widely distributed throughout the cere-
brum of patient II-1 (Supplementary Fig. 3A), are a characteristic
neuropathological feature of pantothenate kinase-associated
neurodegeneration.12–14 More recently, perturbed lipoic acid
biosynthesis has been implicated in the pathological disruption
of mitochondrial oxidative metabolism. Features of these
disorders are varied but, in many cases, include infantile
encephalopathic presentations with severe epilepsy, similar to
that reported in the cases of SMVT deficiency here.15–19
While some degree of phenotypic heterogeneity is evident
between the described sibling pair and the unrelated index case,
the basis of these differences remains uncertain given the small
number of cases identified to date.4 It is likely though, that the
temporal progression of untreated disease in II-2 has contributed
to more severe neurological manifestations. Further delineation of
these findings will be informed by identification and longitudinal
investigation of additional cases.
Despite the fact that biotin, pantothenate and lipoate feed into
numerous biochemical pathways (Fig. 1d, e), biochemical analyses
of metabolites in both our patients and the previously reported
patient did not detect any abnormalities.4 This is suggestive of a
redundancy in B-group vitamin transport within the gastrointest-
inal tract, in contrast to the critical role of SMVT in transport across
the blood–brain barrier, which may explain the neurological
features but lack of biochemical abnormalities.20 It is similarly
interesting that neuroimaging features and pathological findings
specific to the basal ganglia, commonly observed in disorders of
biotin, pantothenate and lipoate metabolism, were not evident in
our patients or the previously described individual.4
The mutations we identified in SLC5A6, V141Afs*34 (29 alleles,
0.01%) and R400T (2 alleles, 0.0008%), have both been observed at
extremely low frequency in the population database gnomAD, but
never in homozygosity.21 The V141Afs*34 variant is predicted to
result in a truncated protein product, removing many of the
functionally important domains (Supplementary Fig. 4B).9,22,23 This
truncation was supported by the cDNA experiment (Fig. 1b),
which also suggested nonsense-mediated decay by displaying
reduced expression of this allele. The R400T variant is located on
an intracellular loop of SMVT, close to a transmembrane domain
(Supplementary Fig. 4B). Multiple species alignment shows the
R400 residue is moderately conserved, retained in 25 of 39
vertebrate species (Supplementary Fig. 4C), with the lysine residue
present in other species having similar chemical properties to
arginine. The molecular basis of impaired SMVT function due to
this missense mutation is unclear.
SMVT deficiency is extremely rare, with only one similar case
being reported to date (Table 1).4 In order to identify additional
patients, we contacted researchers with cohorts of patients
without a genetic diagnosis for suspected mitochondrial and
neurological disease, with existing WES data, as well as sharing the
genotypic and phenotypic information of patient II-2 on Match-
Maker Exchange.24 However, no additional patients with homo-
zygous or compound heterozygous variants in SLC5A6 were
identified.
Table 1 continued
Clinical features This study—patient II-1 This study—patient II-2 Subramanian 2017
Other






Osteopenia No No Yes
Post treatment:
Resolved
Digital clubbing NR Yesp NR
Treatment
Nil Biotin (intramuscular) 10mg weekly
Dexpanthenol (intramuscular) 250mg weekly






GORD gastro-oesophageal reflux disease, NR not reported
aReported at +5 years from commencement of therapy
bReported at +2 years, 9 months from commencement of therapy
cRelative postnatal microcephaly (OFC growth retardation)
dInitial hyperreflexia; progressive obtundation of myotatic reflexes presumed secondary to peripheral neuropathy
eConfirmed by serial nerve conduction studies pre/post treatment
fMost recent pre-treatment study [age]: II-1 [1 year, 12 months]; Supplementary Fig. 2A, II-2 [7 years, 5 months]; Supplementary Fig. 2B and C, Subramanian
[12 months]
gMost recent pre-treatment study [age]: II-2 [5 years, 5 months], Subramanian [6 months]
hPost-treatment EEG [+4 years, 8 months]
iSupplementary Fig. 3B
jInsertion: II-1 (nasogastric tube [2 years, 7 months]; nil gastrostomy), II-2 (gastrostomy [6 years, 3 months]), Subramanian (nasogastric tube [infancy];
gastrostomy [6 months])
kPerforated duodenal ulcer/duodenal artery
lSuspected Mallory–Weiss tear in context of cyclical vomiting
mReported secondary to thrombocytopenia
nFeatures of right heart failure at autopsy, presumed secondary to pre-mortem cardiopulmonary resuscitation
oNo clinical cardiomegaly and normal screening echocardiogram [8 years, 9 months]; non-specific ST segment and T wave changes present on ECG
pDigital clubbing of uncertain aetiology (note: normal high-resolution chest CT)
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The paucity of clinically affected individuals due to pathogenic
variants in SLC5A6 may be explained by the critical role of biotin,
pantothenate and lipoate in numerous metabolic pathways. The
SMVT protein is solely responsible for intestinal biotin uptake and
has been shown to be responsible for 89% of biotin transport across
the blood–brain barrier.9,20,25 It is therefore likely that carrying
biallelic amorphic alleles, resulting in no functional SMVT protein, is
lethal. This is supported by the absence of homozygous loss-of-
function variants in gnomAD. Conversely, individuals with two
hypomorphic alleles may have sufficient residual SMVT function to
remain clinically asymptomatic. This is similar to that observed in
other metabolic disorders, such as biotinidase deficiency, where
patients carrying two alleles with residual function are clinically
well.6 Both the earlier described patient and our patients carry a
single amorphic (null) allele in combination with a hypomorphic
allele, likely resulting in sufficient transporter activity to support life,
but inadequate to meet biological demands after birth.4
Complete SLC5A6 knockout mice have not been reported. Only
one-third of conditional (intestine-specific) SLC5A6 knockout mice
were viable and display growth retardation, decreased bone
density and histological abnormalities of the gastrointestinal tract,
overlapping with phenotypic features (e.g. gastrointestinal bleed-
ing and osteopenia) present in the human patients reported to
date.4,25 While the mechanisms underlying these varied clinical
characteristics remain uncertain, it is notable that the phenotype
of the conditional knockout mouse could also be rescued by over-
supplementation of biotin and pantothenic acid.26
For patient II-2, triple replacement therapy was initiated upon
molecular diagnosis of SMVT deficiency at 7 years of age. The case
described in the earlier report commenced treatment at 19 months
of age, which prevented further neurodegeneration and signifi-
cantly improved clinical outcomes in this child.
This is the second report of biallelic SLC5A6 mutations under-
pinning infantile neurodegenerative disease with subsequent
therapeutic response. This result reinforces the importance of
critical cellular cofactors in nervous system function and devel-
opment, and emphasises the potential for significant clinical
benefit, at the individual patient level, that can result from access
to exploratory molecular analysis. Introduction of neonatal or even
preconceptual molecular screening would allow identification of
an increasing number of rare and ultra-rare novel disorders, where
early intervention is supported by therapeutic benefit. In the case
of patients with SLC5A6 mutations, this provides the opportunity
to dramatically attenuate or perhaps even ameliorate neurode-
generation when identified early within the disease course.
METHODS
Patients
Written informed consent to perform WES was obtained under institu-
tionally approved molecular diagnostic consent protocols (SA Pathology),
in accordance with the Declaration of Helsinki. Experimental treatment
regime was approved by the Women’s and Children’s Health Network
Drug and Therapeutics Committee (30 September 2014), and access
obtained following approval under the Australian Government Therapeutic
Goods Administration Special Access Scheme.
Genetic studies
WES was performed on genomic DNA samples from II-1 and II-2 at the
Centre for Cancer Biology ACRF Genomics Facility. Exonic sequences were
enriched using the SeqCap EZ Human Exome Library v3.0 kit (Roche
NimbleGen) and libraries sequenced as 100 bp paired-end reads on the
HiSeq 2000 platform (Illumina).
Read alignment to the UCSC human genome assembly hg19 was
performed with the Burrows–Wheeler Aligner (v.0.6.2). Picard was used to
mark duplicates and GATK (v2.7-2) was used for local realignment around
indels and to recalibrate quality scores. SNV’s and small insertions and
deletions were detected using GATK’s Unified Genotyper (v2.7-2).
To rule out sample identity errors, SNP calls from WES data were
compared to calls from the Infinium CytoSNP-850K BeadChip assay
(Illumina), performed according to the manufacturer’s protocol at the
Centre for Cancer Biology ACRF Genomics Facility on genomic DNA samples.
Variant filtering and prioritisation
WES results were first investigated for variants in OMIM genes known to be
causative of neurodegeneration, but no likely pathogenic variants were
identified. Results were then filtered to highlight potentially causative
variants under three modes of inheritance: autosomal recessive with
homozygous or compound heterozygous variants, and autosomal
dominant due to parental mosaicism. Variants were only considered if
they were present in both affected children, were predicted to cause a
functionally important effect (SNPEFF effect moderate or high) and were
rare in the general population (ExAC MAF <1% for AR or <0.1% for AD).21
Variants were further prioritised by only considering those predicted to be
pathogenic by in-silico programmes (CADD score >20) and in conserved
regions (GERP score >2). Variants present in concordant zygosity in our in-
house genomic variant database were excluded (Supplementary Table 1).
Candidate variants from WES were confirmed and co-segregation
assessed by Sanger sequencing of PCR-amplified genomic DNA from
affected and unaffected family members.
Gene expression analysis
Total RNA was extracted from dermal fibroblasts (I-1, I-2, II-1 and II-2) using
the RNeasy Mini Kit (Qiagen). Reverse transcription was performed using
the SuperScript III Reverse Transcriptase kit (Invitrogen), as per the
manufacturer’s instructions, with 150 ng of Random Primers (Promega) and
1 μg of total RNA. RNA complimentary to cDNA was removed using 1 μL of
RNase H (Invitrogen). Gene expression was assessed by Sanger sequencing
of PCR-amplified cDNA.
Cell culture
HeLa cell cultures were maintained in Dulbecco’s modified Eagle medium
(DMEM) with 20mM HEPES, supplemented with 10% foetal bovine serum
(Sigma-Aldrich) and 1% penicillin–streptomycin–glutamine (Gibco). Cells
were split every 3–4 days at a ratio of 1:2. HeLa cells were purchased from the
American Type Culture Collection (ATCC, Reference CCL-2). Primary dermal
fibroblast cultures were established following skin biopsy of I-1, I-2, II-1 and II-
2 at the Women’s and Children’s Hospital, Adelaide. Cultured fibroblasts were
maintained using basal Eagle’s medium 1 × (BME) (Gibco) with 10% foetal
bovine serum, 1% L-glutamine, 200mM and 1% penicillin–streptomycin (all
from Sigma-Aldrich). Cells were split every 7–10 days at a ratio of 1:2.
Generation of expression constructs
Wild-type SLC5A6 expression clones were obtained from OriGene
(RC204865). Mutant alleles were created by site-directed mutagenesis,
following the manufacturer’s protocol for the Quikchange II XL Site-
Directed Mutagenesis Kit (Stratagene). Products were incubated with the
DpnIrestriction enzyme to digest the parental (non-mutated) plasmid
dsDNA. Wild-type, mutagenized and pCMV6-entry empty vector clones
were transformed into XL-10 Gold Ultracompetent Cells (Agilent Technol-
ogies) and incubated overnight. Single colonies were grown overnight in
liquid culture and clones purified using the QIAfilter Plasmid Midi Kit
(QIAGEN). The entire SLC5A6 insert in wild-type and mutant clones was
verified by Sanger sequencing in both directions.
Transfection of HeLa cells
HeLa cells were transfected using the Lipofectamine 3000 reagent
(Invitrogen) according to the manufacturer’s protocol. Cells were seeded
in 12-well plates (2 × 105 cells) and incubated overnight. The following day,
cells were transfected using 0.25 and 1 μg, respectively, of empty-vector,
wild-type or mutant expression construct.
Biotin uptake assay
Biotin uptake studies were performed using primary dermal fibroblasts (I-1,
I-2, II-1 and II-2), and HeLa cells transfected with empty-vector pCMV6 or
constructs expressing wild-type SLC5A6 or mutant protein.27 Dermal
fibroblasts were seeded in 12-well plates (2.5 × 105 cells) in basal Eagle’s
medium 1 × (BME) (Gibco) with 20% foetal bovine serum (Sigma-Aldrich)
A.B. Byrne et al.
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and 1% L-glutamine. 24 h after seeding, cells were incubated in
Krebs–Ringer buffer (133mM NaCl, 4.93mM KCl, 1.23mM MgSO4,
0.85mM CaCl2, 5 mM glucose, 5mM glutamine, 10mM HEPES and 10mM
MES, pH 7.4) containing 20 nM 3H biotin (American Radiolabeled Chemicals).
Biotin uptake was measured after 24 h by washing cells twice with 1ml of
ice-cold Krebs–Ringer buffer then lysed in 0.2ml of 1M NaOH. Radioactive
content in the cell lysates was quantitated using a scintillation counter with
OptiPhase Supermix scintillation cocktail (Perkin Elmer). Protein content in
the lysates was measured using a Bradford protein assay kit. Uptake assays in
transfected HeLa cells were performed as above except cells were incubated
in Krebs–Ringer buffer containing 80 nM 3H biotin for 24 h post-transfection.
Each transfection and uptake assay were performed in triplicate, and the
results calculated as cpm/mg of lysate. The data from four discrete assays (n
= 4) was combined for statistical analysis. A two-tailed Student’s t-test was
performed comparing the empty vector and expression constructs.
Reporting summary
Further information on experimental design is available in the Nature
Research Reporting Summary linked to this paper.
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